{"name":"Apurano Pharmaceuticals GmbH","slug":"apurano-pharmaceuticals-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Adezunap","genericName":"Adezunap","slug":"adezunap","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Adezunap (AP707)","genericName":"Adezunap (AP707)","slug":"adezunap-ap707","indication":"Autoimmune hepatitis","status":"phase_3"}]}],"pipeline":[{"name":"Adezunap","genericName":"Adezunap","slug":"adezunap","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adezunap (AP707)","genericName":"Adezunap (AP707)","slug":"adezunap-ap707","phase":"phase_3","mechanism":"Adezunap is a small-molecule inhibitor of adenosine deaminase that increases intracellular adenosine and deoxyadenosine levels to promote immune cell apoptosis and reduce inflammation.","indications":["Autoimmune hepatitis","Primary biliary cholangitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQODRSeHZ1WTg0bnVlRGJqRlNEbDQzZGZ6ejQxNGI0amtJR19NQ1dEeFY5Y2x2MkxpU0pMY1VHSlFkNnRpZy02OGcybmNJdW9YcXJJRmcwUnFQMUNhUDNmTWlMbjdoeFdMVTJTVXUtbjUyeERyWHRqT3dJQkx0TklXRjVzUFNQZHU1WFIyNDdpekFXenprZFc3Z3VXM3FhazBVX202Ukk4S01xMTBGem5ZNE9Xc3V0ZHV4MVpDYk4zVWVSTjNfZnVBN0NyWFZNUk13QVF6ckFObUJhajh4QVNsbjJWWGZieVhxQU9LN3VaWFJCcXZMakZUZDU5MjZsQkJmX0FSWWtxNU5JbXdZWTF0Wnc4SlA3SzJweU9LcHBXYXlCTndxTVliSlh0LU9ta3Qtb1ItV2xrZVVta0k2MWc?oc=5","date":"2025-01-30","type":"trial","source":"GlobeNewswire","summary":"Chronic Pain Clinical Trial Pipeline Experiences Momentum: - GlobeNewswire","headline":"Chronic Pain Clinical Trial Pipeline Experiences Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPb0s0Tld3QnJ2c2Z4aFlVUzRIOUpjNkZyWVQyRDhuX3E1OHNZdkRhWklNM0Rlb2ZsUmZHdWUxZWZtSFctbzBhZk8zcjVOTDlSR0plaWs0S0JranMyUXFzeVBxc0ZZc1E5VE0wdU9sUXRSRlRhQ2d2VG9keVptMk5wWnJUQXN3WkFpaUE4TnI3QUtsWHd2RUhKX2s3ZEJNS0lOZWtjV0ktcTl3Nmx4MVdQalpPcDNmWTA?oc=5","date":"2024-05-22","type":"pipeline","source":"IQVIA","summary":"No pain some commercial gain: Non-Addictive Prescription Medicines - IQVIA","headline":"No pain some commercial gain: Non-Addictive Prescription Medicines","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}